QNCX Q3 EPS Increased by Brookline Capital Management

Key Points

• Brookline Capital Management has raised their Q3 2025 earnings per share estimate for Quince Therapeutics from ($0.25) to ($0.19).
• Citigroup and Citizens JMP issued new ratings for Quince Therapeutics, with Citigroup giving an "outperform" rating and Citizens JMP assigning a "strong-buy" rating with a $9.00 price target.
• Quince Therapeutics' recent earnings report revealed a loss of ($0.34) EPS, which missed the consensus estimate of ($0.28) by ($0.06).

Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Research analysts at Brookline Capital Management raised their Q3 2025 earnings per share estimates for Quince Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Brookline Capital Management analyst K. Raja now expects that the company will earn ($0.19) per share for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Quince Therapeutics' current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics' Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.04) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at $0.15 EPS.

QNCX has been the topic of a number of other research reports. Citizens Jmp assumed coverage on shares of Quince Therapeutics in a report on Tuesday, August 5th. They issued a "strong-buy" rating and a $9.00 target price on the stock. JMP Securities dropped their target price on Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating on the stock in a report on Tuesday, August 12th. Citigroup assumed coverage on Quince Therapeutics in a report on Tuesday, August 5th. They set an "outperform" rating for the company. D. Boral Capital reissued a "buy" rating and issued a $4.00 price target on shares of Quince Therapeutics in a research report on Friday, August 15th. Finally, Wall Street Zen cut Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Three investment analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to data from MarketBeat.com, Quince Therapeutics has a consensus rating of "Buy" and a consensus target price of $8.14.

Quince Therapeutics Stock Up 1.2%

Shares of Quince Therapeutics stock traded up $0.0190 during trading hours on Friday, reaching $1.6290. The company's stock had a trading volume of 37,908 shares, compared to its average volume of 236,128. The company has a market capitalization of $87.49 million, a P/E ratio of -1.49 and a beta of 1.02. The stock's fifty day simple moving average is $1.63 and its two-hundred day simple moving average is $1.37. Quince Therapeutics has a one year low of $0.5609 and a one year high of $2.45. The company has a debt-to-equity ratio of 1.45, a quick ratio of 5.00 and a current ratio of 5.00.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06).

Institutional Trading of Quince Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its position in shares of Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock valued at $703,000 after acquiring an additional 36,807 shares during the last quarter. Northern Trust Corp increased its position in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after purchasing an additional 16,501 shares during the last quarter. Shay Capital LLC increased its position in shares of Quince Therapeutics by 60.8% in the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after purchasing an additional 104,616 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Quince Therapeutics in the fourth quarter valued at approximately $57,000. Finally, Intellectus Partners LLC bought a new stake in Quince Therapeutics during the first quarter valued at approximately $71,000. Hedge funds and other institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.